Navigation Links
MultiVu Video Feed: WELCHOL (R) (COLESEVELAM HCL) RECEIVES FDA APPROVAL FOR GLUCOSE CONTROL IN ADULTS WITH TYPE 2 DIABETES MELITUS
Date:1/18/2008

Daiichi Sankyo, Inc. announced today that the United States Food and Drug Administration (FDA) has approved WelChol(R) (colesevelam HCl) Tablets as the first LDL cholesterol lowering medication also indicated for improving glycemic control in adults with type 2 diabetes mellitus (DM) in combination with metformin, sulfonylureas, or insulin, when these agents are used alone or in combination with other anti-diabetic agents.

The ADA estimates that 20.8 million people in the United States have diabetes and more than 90% of these have type 2 diabetes. People with diabetes face significantly higher risk of developing cardiovascular disease. It is estimated that approximately half of all Americans have elevated blood cholesterol levels that can negatively impact their health and quality of life. According to a recent Harris Interactive Survey, approximately 29% of adults previously diagnosed with hypercholesterolemia have also been diagnosed with diabetes. Given the prevalence of diabetes and high LDL cholesterol, a medication that can help lower both A1C and LDL cholesterol can be beneficial for many patients. Welchol is a new option that addresses these two chronic health conditions and provides physicians with a different therapeutic approach for treating patients with type 2 diabetes.
For more information, please visit http://www.dsus.com.

SATELLITE FEED:

Friday, January 18th, 2008

6:30 PM - 6:45 PM ET

Galaxy 25

C-Band

Transponder 14

Downlink Freq. 3980 Horizontal

Preview and access this video on Pathfire DMG: Slug # 29711

Search within the PR Newswire or MultiVu section by story ID # 29711 or by headline

For technical assistance call Pathfire Customer Care at 1-888-345-0489 or e-mail support@pathfire.com

NEWS: WelChol Receives FDA Approval To Reduce Blood Glucose in Adults with Type 2 Diabetes

FORMAT: B-roll and Soundbites.

ADDITIONAL RESOURCES: Video, contact information and more available at: http://www.prnewswire.com/broadcast/29711/press.html

SOUNDBITES:

* Dr. Ronald B. Goldberg, Professor of Medicine and Professor,

Biochemistry and Molecular Biology at the University of Miami and the

Associate Director of the Diabetes Research Institute

B-ROLL INCLUDES:

* Doctor/Patient footage

* Patient lifestyle & footage

* Product shots/manufacturing footage

* Daiichi Sankyo exteriors

VIDEO PROVIDED BY: Daiichi Sankyo

Contact: FOR MORE INFORMATION, PLEASE CALL: MultiVu Media Relations, 1-800-653-5313 EXT. 3


'/>"/>
SOURCE Daiichi Sankyo
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Photo: MultiVu Promotes George DeTorres to Divisional Vice President for the MultiVu Healthcare Team
2. MultiVu Video Feed: NEW SURVEY FINDS THAT HALF OF CAREGIVERS SPEND 10 PERCENT OF THEIR INCOME CARING FOR AN OLDER LOVED ONE
3. MultiVu Video Feed: STARLIGHT STARBRIGHT UNVEILS GET FIT, GET RIGHT A PROGRAM TO PREVENT TYPE 2 DIABETES AND WEIGHT-RELATED CONDITIONS IN TEENS
4. MultiVu Video Feed: Parents of Kids With Infectious Diseases Sounds Alarm About the Dangers of Pertussis With "Silence the Sounds of Pertussis" Campaign
5. MultiVu Video Feed: FDA Approves DORIBAX(TM) (doripenem for injection) for the Treatment of Complicated Intra-abdominal and Complicated Urinary Tract Infections
6. MultiVu Video Feed: PUBLIC HEALTH EXPERTS CONVENE TO DISCUSS THE TREATMENT AND PREVENTION OF RABIES
7. VIDEO from Medialink and The Leukemia & Lymphoma Society: Saving Lives One Mile at a Time
8. VIDEO from Medialink and Stryker: New Alternative to Hip Replacement Surgery
9. InfoLogix Featured in FOX Business News Interview on Reducing Healthcare Medication Errors - Video Available Online
10. VIDEO from Medialink and Revolution Health: RevolutionHealth.com Launches Resolutions 2.0
11. VIDEO from Medialink and GlaxoSmithKline: Really Think You Can Lose 30 Pounds in 30 Days?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... ... August 17, 2017 , ... An August 2 article ... obtaining plastic surgery, largely influenced by the growing popularity of “pretty boys” in both ... notes that standards of male appearance are changing not only in the Asian nation, ...
(Date:8/17/2017)... ... 2017 , ... Pot Valet is a leading provider of premium medical-grade cannabis ... state, and soon, every state in the country, the company offers patients safe, legal, ... altogether. , According to Pot Valet, all California patients have the legal ...
(Date:8/17/2017)... (PRWEB) , ... August 17, 2017 , ... A recent ... to the biopharmaceutical industry in 2016 cited deficiencies in data integrity. The FDA outlines ... Part 11 ruling. , Presented as part of the Beckman Coulter Life ...
(Date:8/16/2017)... Los Angeles, California (PRWEB) , ... August 16, 2017 , ... An August 3rd ... patients that was the subject of a report in JAMA (the Journal of the American ... (BMIs) above 50 were able to achieve BMIs under 30, when compared to patients with ...
(Date:8/16/2017)... ... August 16, 2017 , ... For the second ... England student to educate the public on the impact of concussions. Brooke Mills, ... first-ever National Concussion Awareness Day. , Brooke is working diligently is to raise ...
Breaking Medicine News(10 mins):
(Date:7/28/2017)... 28, 2017 Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: ... quarter ended June 30, 2017, and updated its financial ... For the fiscal third quarter, Hill-Rom reported ... per diluted share in the prior-year period. These results ... per diluted share primarily related to the non-cash write-down ...
(Date:7/27/2017)... Pharmaceutical Services, Inc. (NYSE: WST ) today ... updated financial guidance for the full-year 2017. ... Reported net sales of $397.6 million, a record ... at constant currency (organic) grew by 3.9%. ... $0.60 in the prior-year quarter. Second-quarter 2017 adjusted diluted ...
(Date:7/26/2017)... July 26, 2017 Sancilio Pharmaceuticals Company, Inc. ... clinical trial evaluating Altemia TM , an oral therapy ... Sickle Cell Disease (SCD). The SCOT Trial, is a ... and safety of Altemia TM in pediatric patients ... US IND 125274. ...
Breaking Medicine Technology: